The effects of ezetimibe and/or orlistat on triglyceride-rich lipoprotein metabolism in obese hypercholesterolemic patients.
We investigated the factors influencing triglycerides (TG) reduction during ezetimibe, alone or combined with orlistat, administration. Eighty-six obese hypercholesterolemic subjects were prescribed a low-fat diet and were randomized to ezetimibe (E group), orlistat (O group), or both (OE group) for 6 months. Plasma TG and apolipoprotein (apo) C-III reduction was significantly greater in the combination group compared with monotherapy. Multivariate analysis showed that in E group apoC-III reduction and baseline TG levels were independently positively correlated, whereas baseline apoC-II levels were negatively correlated, with TG lowering. In OE group apoC-III reduction was the only independent contributor to TG reduction.
Nakou
E S
ES
Department of Internal Medicine, School of Medicine, University of Ioannina, 45 110 Ioannina, Greece.
Filippatos
T D
TD
Agouridis
A P
AP
Kostara
C
C
Bairaktari
E T
ET
Elisaf
M S
MS
D019440:Anti-Obesity Agents / Q000494:pharmacology*; D000924:Anticholesteremic Agents / Q000494:pharmacology; D053304:Apolipoprotein C-II / Q000378:metabolism; D053305:Apolipoprotein C-III / Q000378:metabolism; D001384:Azetidines / Q000494:pharmacology*; D018752:Diet, Fat-Restricted; D004359:Drug Therapy, Combination; D000069438:Ezetimibe; D005260:Female; D006801:Humans; D007783:Lactones / Q000494:pharmacology*; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000178:diet therapy / Q000188:drug therapy*; D000077403:Orlistat; D014280:Triglycerides / Q000378:metabolism*
D019440:Anti-Obesity Agents; D000924:Anticholesteremic Agents; D053304:Apolipoprotein C-II; D053305:Apolipoprotein C-III; D001384:Azetidines; D007783:Lactones; D014280:Triglycerides; D000077403:Orlistat; D000069438:Ezetimibe